Condition
Amyloidosis, Familial
Total Trials
5
Recruiting
3
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
60%
3 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 3 (3)
Trial Status
Recruiting3
Completed1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06672237Phase 3Recruiting
A Phase 3 Study of NTLA-2001 in ATTRv-PN
NCT07213297Recruiting
Comprehensive Program for Hereditary Transthyretin Amyloidosis
NCT07116473Phase 3Not Yet Recruiting
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT05489549Recruiting
Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
NCT03862807Phase 3CompletedPrimary
Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant
Showing all 5 trials